Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Langer C.JGadgeel S.MBorghaei HPapadimitrakopoulou V.APatnaik APowell S.FGentzler R.DMartins R.GStevenson J.PJalal S.IPanwalkar ACHIH-HSIN YANGGubens MSequist L.VAwad M.MFiore JGe YRaftopoulos HGandhi LKEYNOTE-021 investigators2020-05-262020-05-2620161470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994430500&doi=10.1016%2fS1470-2045%2816%2930498-3&partnerID=40&md5=f418d819d3ac9906211ec981dfbeb11chttps://scholars.lib.ntu.edu.tw/handle/123456789/494970[SDGs]SDG3Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyjournal article10.1016/S1470-2045(16)30498-3277458202-s2.0-84994430500